Life Sciences Archive » April, 2026

Life Sciences - April, 2026

289 articles

• Medtronic User Says Data Hack Exposed 9M Client Records
• Acadia Investors Get Final OK For $179M Deal, Atty Fees
• Jury Begins Mulling If Doctors Are Liable For Fatal Overdose
• Trump Taps 3rd Surgeon General Pick, Drops Casey Means
• Crypto Co. Fights Shkreli's Counterclaims In Album Case
• Supplement Industry Says FDA Wrongly Muzzled Label Claims
• Previewing FDA National Priority Vouchers In Psychedelics EO
• Critical Mineral Restrictions Up 500% From 2009, OECD Says
• NJ University Can't Escape Ex-Professor's Age Bias Suit
• Playing Magic: The Gathering Makes Me A Better Lawyer
• Goodwin, Davis Polk Lead Avalyn's Upsized $300M IPO
• Why Product-Based Public Nuisance Claims May Be Waning
• NC Biz Court Bulletin: Corporate Raid, MV Realty Settlement
• J&J Says Ill. Ruling Backs Beasley Allen's DQ From Talc Suits
• Purdue's $125M McKinsey Deal Gets OK Ahead Of Ch. 11 Exit
• Express Scripts, Cigna Seek End To Ohio PBM Price Suit
• Kratom Seller Sanctioned For Deleting Blog During Suit
• J&J, Neutrogena Say FDA Signed Off On Benzene Products
• Feds Say Lack Of Injury Dooms Gold Card Program Challenge
• High Court Seeks Path To Limited Ruling On 'Skinny Labels'
• Deloitte Can't Duck Bulk Of Vax Software Theft Suit
• Squires Snubs 10 IPRs While 4 Pass Muster In Latest Order
• CEO Stole From His Company To Buy Mansion, SEC Says
• 3 Federal Circuit Clashes To Watch In May
• Novo Nordisk Rejects Claim It Influences GLP-1 Market
• PBMs Say Michigan AG Price-Fixing Suit Is Unsound
• Improving Well-Being In Law, 10 Years After Landmark Study
• How To Gear Up For Trump's Pharma Tariffs
• Teva Acquires Tourette's Drugmaker For Up To $900M
• Bausch Balks At Suspected Tweak In Price-Fixing Deals
• AbbVie Seeks Early Win Over HHS In Botox Drug Price Suit
• Ropes & Gray Guides Italy's Chiesi On $1.9B US Biotech Deal
• Hogan Lovells Rehires Baker McKenzie Chair As Partner In DC
• Allergan Seeks Sanctions Over Discovery In Botox Fight
• 5th Circ. Judge 'Hung Up' On FDA Vape Denial Reasoning
• Teleflex Settles Catheter Patent Case Against Medtronic
• Ex-Fauci Adviser Charged With Concealing COVID Records
• Purdue Pharma's $5.5B Plea Deal Clinched As Survivors Protest
• MedMal Case Volume Declines, But Doctor Risks Remain High
• Paul Hastings, Gibson Dunn Steer $739M Ligand-Xoma Deal
• Walgreens Can't Use Recording To Undo Investor Claim In Ill.
• Chinese Man Extradited From Italy Over COVID Data Theft
• Hikma, Cipla Cut Deals In Pfizer Heart Drug Patent Case
• Maryland Justices Allow IVF Cost Class Action To Proceed
• Eli Lilly Inks $2.25B AI Genetics Research Pact With Profluent
• Meet The Attys Arguing The High Court 'Skinny Label' Case
• North Dakota Drug-Pricing Law Blocked In Pharma Fight
• Did Hedge Fund 'Greed' Hurt Vaxart Investors? Jury To Decide
• DOJ Says Wash. 340B Drug Law Is Preempted In Novartis Suit
• High Court Appears Split In Monsanto Roundup Appeal
• How The Coming Months Will Shape State Drug Price Boards
• Moderna Hit With Suit Over CureVac COVID Patents
• Attys, Advocates Call DOJ Pot Rule Historic Shift For Feds
• IQVIA Accuses Ex-Execs, Syneos Of Poaching $180M Client
• High Court 'Skinny Label' Case Will Matter To Tech Litigators
• 4 Firms Build Astorg's $1.1B Microbiology Biz Buy
• 3rd Circ. Panel Once Again Backs Talc Co. Whittaker's Ch. 11
• Bioscience Co. Allegedly Hid Volatility Risks From Investors
• McCarter & English Plans New Waterfront Home In Boston
• Catching Up With Delaware's Chancery Court
• What To Watch As Justices Take On 'Skinny Label' Case
• Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy
• US, Indian Firms Guide $11.75B Sun Pharma-Organon Deal
• How Food, Beverage Claims May Preview Cosmetic Litigation
• Up Last At High Court: TPS, Geofence, Skinny Labels
• Natera Tells Justices CareDx Made Up Circ. Split In Petition
• NY Court Pauses $100M Saudi Arabia Pharma Award Suit
• What's At Stake As High Court Hears Roundup Appeal
• Danaher Execs Face Investor Suit Over Post-COVID Outlook
• Court's HRSA Policy Reversal Leaves 340B Rules Murky
• Merck's $6.7B Terns Deal Clears Regulatory Hurdle
• Pfizer, Dexcel Drop Heart Drug Case Before Bench Trial
• Biotechs Clash Over Cancer Drug Discovery In Chancery
• Taxation With Representation: Gibson Dunn, Paul Weiss
• Latest Squires Order Grants 5 IPRs, Denies 4 On The Merits
• Full Fed. Circ. Urged To Rethink Corcept Patent Loss
• FTC Cuts Deal To End Anesthesia Group Rollup Case
• Pa. County Joins Insulin-Pricing Suit Blitz Against CVS, PBMs
• Kirkland To Add Tenn. SG Behind Skrmetti Supreme Court Win
• Firm Seeking Philly Zantac Judge's Recusal Appeals Refusal
• Officiating Football Makes Me A Better Lawyer
• ITC Investigating Chinese Biopharma Chemicals Over Pricing
• DOJ Says Medical Pot Shift Shouldn't Affect Gun Rights Case
• Trulieve Says Infringement Suit Doesn't Actually State A Claim
• DOJ Final Order Loosens Rules For State-Legal Medical Pot
• Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid
• Bayer 'Natural' Vitamin Buyer Classes Affirmed By 9th Circ.
• Eli Lilly Case Over Weight Loss Drugs Kept Mostly Intact
• Justices Would Back Vax Law Challenge, 2nd Circ. Told
• Judge Lets Pharma Co. Seal Parts Of Ex-GC's Retaliation Suit
• Fresenius Ruling May Shift Anti-Kickback Enforcement
• Sorrento, M3 Get Pause On RICO Suit Naming Jackson Walker
• Written Consent Ruling May Signal Change For Telemarketing
• Oura Hit With New Patent Suit Over Fitness Wearables
• Law School's Missed Lessons: How To Draft Pleadings
• Ex-Conn. Prosecutor Fights Drug Co. Bid To Appeal DQ Denial
• 4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy
• Chancery Sends Masimo Ex-CEO Pay Fight To California
• Armistice Capital Head Calls COVID Stock Rise 'Fun,' 'Lucky'
• Merck Beats Minn. Hockey Player's Talc Mesothelioma Claims
• Biotech Co. Investors Clash Over 'Self-Dealing' Claim
• Congress Rallies More For Bills On Copyrights Than Patents
• Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge
• Pfizer, Dexcel Take 2 Patents Off Table For Bench Trial
• At The Fed. Circ., Means-Plus-Function Is Not Quite Dead
• Fed. Circ. Keeps Banner Witcoff And Saiber Off Patent Case
• Pot Management Co. Says It's Allowed Biz Tax Deduction
• Squires Stands By Ending Skincare IPR Over ITC Overlap
• Novo Nordisk Unit Can't Slip Former Exec's Sex, Age Bias Suit
• Purdue Pharma Sentencing Punted For In-Person Attendance
• E-Discovery Quarterly: Recent Rulings On ESI Control
• Ga. Justices Confront Fed, State Power Divide In Bio-Lab Suit
• Philly Zantac Judge Again Declines To Recuse From Cases
• Armistice Head Testifies He Accidentally Deleted Texts
• Beasley Allen Pro Hac Vice Revoked In Philly J&J Talc Cases
• Quinn Emanuel May Face More Sanctions In Guardant Fight
• Philip Morris Unfairly Gains From Label Ruling, 11th Circ. Told
• ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says
• SEC Says Adviser Traded On Firm Clients' Confidential Info
• PFAS Plaintiffs Say Midcase Appeal Would 'Derail' Litigation
• PBMs Fail To Freeze Discovery In Mich.'s Drug-Pricing Case
• She Has A Point: Fish & Richardson's Nitika Gupta Fiorella
• Doctors Fueled Man's Fatal Opioid Addiction, Philly Jury Told
• USPTO Should Let Inventors Valuate Patents In Prosecution
• Justices Mull Limits On Federal Review Of State Cases
• House Panel Probes Reports Of Missing, Killed Scientists
• GSK, Moderna Both Ordered To Provide More Info In Vax Fight
• Trump Orders Agencies To Fast-Track Psychedelic Therapies
• White & Case Partner Moves To A&O Shearman In DC
• Kirkland, Goodwin Guide Lilly's Potential $7B Kelonia Buy
• High Court Won't Hear 3rd Circ. J&J Class Cert. Appeal
• Justices Won't Consider IP Theft Allegations Against Akin
• Bayer Loses Bid To Block J&J's Cancer Drug Survival Claims
• ITC Clears Apple's Redesigned Apple Watch For Import
• Missed Deadline Fatal To Patient's Stapler Suit, 4th Circ. Says
• Kenvue Says Shea & Cocoa Butter Oil Is Accurately Labeled
• 3 Key Questions On Trump's Pharma Tariffs
• AI Health Co. Illegally Shared Genetic Data, Patients Say
• Judge Says Biotech Co. Can't Wipe Cancer Data, For Now
• Life Sciences Firm Says Ex-VP Took Trade Secrets To Rival
• Aramark Joins NJ Insulin Pricing Suits Against PBMs
• Polsinelli Sent Bogus Infringement Letters, Suits Say
• Latham Leads Kailera's $625M IPO In Obesity Drug Push
• Doc Says Texas Man Can't Sue Over Mailed Abortion Pills
• 2 Discovery Rulings Break With Heppner On AI Privilege Issue
• Fed. Circ. Reverses $18M Penile Implant Trade Secret Win
• Trump Taps Ret. Rear Admiral Schwartz As New CDC Chief
• Wis. Supreme Court Upholds Pabst Asbestos Verdict
• Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win
• IV Device Redesign Not Enough To Lift Ban, CBP Says
• Isshin-Ryu Karate Makes Me A Better Lawyer
• USPTO Ends COVID Patent Appeals Program
• Katten Partner Rejoins Epstein Becker In DC For 3rd Time
• Consumer Cases Drive Class Action Spike, Report Says
• Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit
• Drugmaker Aquestive's Brass Sued Over FDA Setback
• Ex-DOJ Antitrust Atty On Google Case Joins Wilson Sonsini
• Squires Passes On 10 Patent Challenges, Takes On 2 Others
• NC Judge Won't Undo $4M Philips Copyright Verdict
• Microplastics On Water Contaminant List Could Spur Claims
• USPTO's AI Search Pilot May Reshape Patent Filing Strategy
• Willkie Adds O'Melveny Litigator To Los Angeles Office
• Biopharma Co. Says Ex-Worker Used Files To Build AI Rival
• Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told
• 4th Circ. Revives Pharma Bid To Block Maryland's 340B Law
• States Denied Time For Talks To Settle Drug Price-Fixing Suit
• Justices Told That Eli Lilly's FCA Qui Tam Challenge Too Late
• Trade Group Latest To Sue Wash. Over 340B Drug Pricing Law
• Vertex Sues Former Exec To Block Move To Rival
• FDA Offers Guidance On Safety Testing For Gene-Editing Tech
• Peptide Policy Is Shifting Toward Sanctioned Compounding
• 3rd Circ. Upholds J&J Injunction Bid Loss In Biosimilar Fight
• Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal
• Mich. AG Says PBMs Can't Duck Drug-Pricing Suit
• 4th Circ. Won't Rehear Allergan Overcharge Suit
• Buyers Seek Final Approval Of $4.85M Bayer Benzene Deal
• Avanos Medical Going Private In $1.3B Deal Led By 3 Firms
• Keys To Building Defensible Psychedelic Therapy Programs
• State AGs, Albertsons Chain Reach $773M Opioid Deal
• Omnicare OK'd For Ch. 11 Auction With $250M Base Bid
• Oracle Wins TRO Against Ex-Worker Threatening Secrets Sale
• Citron's 'Shadowy Gang' Sued Over Short Selling Campaign
• Ill. Judge Wants More Proof To Recalculate Kickback Damages
• FTC Ends Teen Height Growth Supplement Claims
• Del. Judge Ends 80K Pre-2026 Zantac Cases
• Obesity Drugmaker Leads 2 Biotech Startups Eyeing IPOs
• Mylan Can't Revive Copaxone Antitrust Claims Against Teva
• Hikma Tells Justices Cox Ruling Boosts 'Skinny Label' Case
• VC Apple Tree Seeks $7M As Judge Mulls Ch. 11 Funding Fight
• AI Cardiac Imaging Co. Hits Ex-Consultant With IP Suit
• Inventors Face Bayh-Dole Act Reporting Issues, GAO Says
• Texas GLP-1 Compounder Caused Mom's Death, Family Says
• 11th Circ. Backs FDA's Ban Over Drug Tester's Conviction
• Chamber, Other Biz Groups Back Insulin Cos. At High Court
• Ex-Med Spa Workers Settle Conn. Poaching Claims
• State Bars Need To Get Specific About AI Confidentiality
• Medtronic Can't Ax $382M Trial Loss, Applied Medical Says
• Chest Binders Become Latest Front In Anti-Trans Litigation
• Chinese Scholar Gets Time Served For Smuggling E. Coli DNA
• NJ Justices Won't Review Beasley Allen's DQ From Talc Cases
• Drugmakers Can Intervene In Texas, Fla. Abortion Drug Suit
• Elevance Can't Nix Suit Over GLP-1 Coverage For Sleep Apnea
• Taxation With Representation: Goodwin, CMS, Wilson Sonsini
• Ill. Jury Adds $17M Punitive Award To Baby Formula Verdict
• Yale Medical School Can't Nix Fraudulent Insemination Suit
• Irish Mallinckrodt Unit Stuck In Drug Price-Fixing Suit
• Abbott Hit With $53M Verdict Over Baby Formula Harms
• Split 4th Circ. Backs West Virginia Schoolchildren Vax Law
• Merck Beats 295 Zostavax Suits Over Missed Deadlines
• McKinsey Settles Liability For $125M In Purdue Ch. 11
• Nonprofit Insurer Wants To Seek AstraZeneca Claims Revival
• Alpine Skiing Makes Me A Better Lawyer
• Philly Injection Site Row Judge Rejects Nonprofit's 'Ploy'
• Abiomed Can't Escape Blood Pump Patent Case
• Ecolab Says Personal Injury Law Firm Holding Back $148K
• Ex-Pharmacy Director Denies Using Trade Secrets At New Job
• US Again Urges High Court To Back Drug Price Program
• Fed. Circ. Questions Specificity Needed In Oxy IP Invalidation
• Biz Judge Keeps Doc Class Action Against Luxottica, For Now
• AbbVie Says 340B Program Defines 'Patient' Too Broadly
• States Seek Time For Talks To Settle Drug Price-Fixing Suit
• 3M Settles Ex-Worker's COVID Vax Firing Suit
• FDA Guidance May Move Goalposts For Form 483 Responses
• AstraZeneca Wants 25 Opt-Ins Axed From Pay Bias Suit
• Abbott Urges Ill. Jury To Reject Claims Formula Led To NEC
• 2 Strands Of Patent Law In High Court's 'Skinny Label' Case
• Biopharma-Focused Jeito Wraps 2nd Fund With $1.2B In Tow
• Faegre Drinker Hires 2 Venable FDA Partners In DC
• Redesigned Supplement Partially Cleared In Patent Row
• Calif. Dialysis Bill Violates 1st Amendment, 9th Circ. Says
• Judge Says CPB Couldn't Void Harvard Researcher Visa
• NY Fertility Clinic Agrees To Settle Suit Over Destroyed Eggs
• HHS Must Face States' Suit Over RFK's 'Dramatic Overhaul'
• Data Breach Counsel Chided For Flouting NC Court Rules
• Biogen, Investors Reach Deal In Alzheimer's Drug Litigation
• Minn. Can't Unfreeze $243M In Medicaid Funds, Judge Says
• ImmunityBio Filmmaker Traded On Insider Tip, SEC Says
• Mich. AG Says PBMs Can't Stall Discovery In Drug-Pricing Suit
• Texas AG Says DOGE Data Led To Fraud Investigations
• Boehringer Wants Generic For Blockbuster Jardiance Blocked
• RFK Jr. Tweaks HHS Vaccine Policy Panel Membership Criteria
• Judge Won't Alter $631K SEC Penalty Against Atty
• Ayahuasca Church Urges Judge To Halt DEA Enforcement
• Biz Groups Urge 4th Circ. To End Allergan Overcharge Suit
• Bausch, MSN Laboratories Settle Patent Battle Over IBS Drug
• Splenda Loses Bid To End Scientist's Libel Counterclaim
• Judge Slashes Damages For Natera In Invitae Patent Case
• Why MDLs Slow Down — And How To Speed Them Up
• A Check-Up On HHS' Push To Implement AI Infrastructure
• What A Court Doc Audit Reveals About Erroneous Filings
• Settlement In Sight For Amway, Supplement Co. In TM Dispute
• Pfizer Failed To Warn Of Depo-Provera Cancer Risk, Suit Says
• WilmerHale Adds Regulatory Atty From Mayer Brown In DC
• Catching Up With Delaware's Chancery Court
• Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy
• Case-By-Case Guide As Justices Eye Landmark Pharma Law
• Barnes & Thornburg Snags PFAS Expert From Venable
• SEC Moves To Set Up $40M Investor Fund In Cassava Case
• Legislative Update: Cannabis And Psychedelics Bill Roundup
• EPA Eyes Microplastics, Drugs For Drinking Water Watch List
• Law360 Announces The Members Of Its 2026 Editorial Boards
• Mich. Banking Brief: All The Notable Legal Updates In Q1
• Aetna Escapes COVID Testing Payment Suit In Calif.
• NYC Fights Sanctions Over Discovery In IVF Sex Bias Dispute
• Caterpillar Worker's Bankruptcy Dooms Genetic Privacy Claim
• The Road Ahead For Drug Development In The US
• Georgia Midwifery Laws Violate State Constitution, Suit Says
• Squires Gives Go-Ahead To 5 Patent Reviews, Denies 8
• Petition To Repeal Legal Pot Mobilizes A Showdown In Mass.
• Ex-Pharma Exec Hit With $5.3M Fee Award In Del.
• Alexion Beats Trade Secret Claims In Amyndas Suit
• FDA's Crackdown On Drug Ads Conflicts With Precedent
• Trump Orders 100% Pharma Tariff, Modifies Metals Duties
• Snell & Wilmer Names Life Sciences Pro As San Diego Leader
• Teva $35M Delayed Generic Inhalers Deal Gets Initial OK
• Ultramarathons Make Me A Better Lawyer
• Vape Sellers, Makers Evade Ga. Woman's RICO Scheme Suit
• Ex-Wilson Sonsini M&A Co-Head Rejoins Goodwin In SF
• 7th Circ. Says Ill. BIPA Amendment Applies Retroactively
• Berkshire Must Defend Trulieve In Worker Death Suit
• 3 Federal Circuit Clashes To Watch In April
• DC Cannabis Co. Sues Firm Over Botched Grow Facility
• Harvard Researcher Can Get Docs On Prosecution Motives
• Astellas Beats $115M Milestone Claim In Del. Chancery Ruling
• Mass. Cannabis Businesses Say Repeal Bid Misleads Voters
• PBM Opioid Crisis Suit Stays In Federal Court, Judge Says
• CFO Scores $867K Win In Health Device Co. Wage Suit
• Determining When Engineered Biologics May Be Patentable
• Informal Announcements Are Reshaping FDA Regulations